Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 19/20 | 0.51 |
| ▸ | CDK12 | Q9NYV4 | 19/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 17/20 | 0.51 |
| ▸ | CDK9 | P50750 | 17/20 | 0.51 |
| ▸ | CDK7 | P50613 | 6/20 | 0.51 |
| ▸ | CCNH | P51946 | 6/20 | 0.51 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 16/20 | 0.50 |
| ▸ | CDK2 | P24941 | 16/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25591498 | 1.00 | CCNK (0.51) | CCNKCDK12CCNT1CDK9CDK7 | |
| SCHEMBL25595169 | 1.00 | CCNK (0.51) | CCNKCDK12CCNT1CDK9CDK7 | |
| SCHEMBL26324656 | 0.92 | CCNT1 (0.50) | CCNKCDK12CCNT1CDK9CDK7 | |
| SCHEMBL25595033 | 0.92 | CCNT1 (0.50) | CCNKCDK12CCNT1CDK9CDK7 | |
| SCHEMBL26324667 | 0.92 | CCNT1 (0.50) | CCNKCDK12CCNT1CDK9CDK7 | |
| SCHEMBL26324666 | 0.92 | CCNT1 (0.50) | CCNKCDK12CCNT1CDK9CDK7 | |
| SCHEMBL25595069 | 0.92 | CCNT1 (0.50) | CCNKCDK12CCNT1CDK9CDK7 | |
| SCHEMBL25591446 | 0.92 | CCNT1 (0.54) | CCNKCDK12CCNT1CDK9CDK7 | |
| SCHEMBL25581446 | 0.90 | CCNK (0.60) | CCNKCDK12CCNT1CDK9CDK7 | |
| SCHEMBL25581449 | 0.90 | CCNK (0.60) | CCNKCDK12CCNT1CDK9CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4186895-A1 | COMPOUND USEFUL AS CDK7 KINASE INHIBITOR AND USE THEREOF | TYK Medicines Inc. (CN) | 2023-05-31 | — | — | EP | disclosed |